Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcription-polymerase chain reaction

Jin, Hongfang; Yamashita, Toshiharu; Minamitsuji, Yasushi; Omori, Fusayuki; Jimbow, Kowichi

doi:10.1016/j.jdermsci.2003.09.003

Cited by 14 publications

(6 citation statements)

References 26 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Melanin that can be produced by melanocytes is the substance that gives skin, hair and eyes. We considered that the expression of TYRP1 may be disrupted to impair the normal function of melanocytes and the expression level in blood may be an important indicator of melanoma formation, which is consistent with a prior study (Jin et al, 2003). The gene ranked two is DCUN1D1, which is an E3 ubiquitin ligase complex subunit with potential cancer driver activity (Supplementary Table 1).…”

Section: Validation Of Differentially Expressed Genes By Literaturesupporting

confidence: 81%

Detection of candidate melanoma blood biomarkers by RNA-Sequencing

Lv¹,

Liu²,

Wu³

et al. 2013

cge

View full text Add to dashboard Cite

Due to the high lethality of melanoma, the prediction and non-invasive confirmation of potential melanoma patients of disease-free states is of great interest. The detection of circulating melanoma cells in human blood is a non-invasive surrogate marker of melanoma. We used the publicly available RNA-Sequencing (RNA-Seq) datasets from peripheral blood cells of a melanoma patient and healthy primary melanocytes cells as controls. Differentially expressed genes (DEGs) between peripheral blood from melanoma patients and normal melanocytes were identified by HTSeq followed by DESeq. A total of 2,470 DEGs were obtained, which was analyzed by Gene Set Enrichment Analysis. We indicated that the Gene Ontology term neurogenesis is significantly over-represented by the DEG list, which is consistent with the rapid formation of melanoma. In addition, the pathway analysis revealed that several cancer-related pathways are over-represented. We also found several over-represented transcription factors, such as SMAD3, NFAT, which may be important upstream regulators to influence the dysregulation of the DEGs. Finally, we used available publications to validate top two genes in DEG list, while other DEGs may still need further investigation including computational and experimental efforts. Altogether, the top ranked DEGs may represent clinically useful biomarkers from blood, which would help the early diagnosis of melanoma.

show abstract

Section: Validation Of Differentially Expressed Genes By Literaturesupporting

confidence: 81%

Detection of candidate melanoma blood biomarkers by RNA-Sequencing

Lv¹,

Liu²,

Wu³

et al. 2013

cge

View full text Add to dashboard Cite

show abstract

“…The tyrosinase-related proteins 1 and 2 (TRP-1, TRP-2) were thought to be more sensitive markers for the detection of melanoma than tyrosinase but have not shown sufficient sensitivity and specificity in most studies to supplant tyrosinase [11,13,19]. The problem seems not to be the ability to detect circulating melanoma cells but that the presence of circulating melanoma cells does not necessarily correlate with prognosis [15,17,18].…”

Section: Tyrosinase-related Proteins 1 and 2 And Cancer-testis Antigensmentioning

confidence: 99%

Tumor cell and circulating markers in melanoma: Diagnosis, prognosis, and management

Kounalakis

Goydos

2005

Curr Oncol Rep

View full text Add to dashboard Cite

The search is on for biomarkers for use in the diagnosis, staging, prognosis, and management of patients with melanoma. As with many types of cancer, the hematogenous spread of melanoma is a bad prognostic sign, and many groups have attempted to detect circulating melanoma cells in patients with different stages of melanoma. Some studies have used direct extraction of intact tumor cells from the peripheral blood and others the detection of surrogate markers of circulating melanoma cells, such as tyrosinase or MART-1. However, a correlation between the detection of intact melanoma cells in the circulation and prognosis is controversial. Many other biomarkers have also been studied, including lactate dehydrogenase, S100, TA90, and C-reactive protein. Much progress has been made, and preliminary studies have shown promise with many of these markers. Finally, the detection of tumor-specific circulating DNA has shown promise as a prognostic and diagnostic marker of disease in melanoma as well. In this review we examine the most promising biomarkers for use in patients with cutaneous melanoma.

show abstract

“…8,9 Circulating tumor cells have been detected by quantitative RT-PCR assays measuring the expression of different genes as tumor markers, such as tyrosinase, MART-1, TRP-1, MAGE-A3 and MITF. [10][11][12][13][14][15] Because of the heterogeneous expression of melanoma genes, the variable performance of the assays and the implementation of novel techniques, the clinical utility of circulating tumor cell markers has not yet reached a general consensus. 16 Circulating cell free tumor DNA has been detected in plasma and serum by assessing allelic imbalance at microsatellite markers [17][18][19] and tumor-related gene methylation.…”

mentioning

confidence: 99%

Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients

Daniotti

Vallacchi

Rivoltini

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

BRAFV600E is the most represented somatic point mutation in cutaneous melanoma, thus providing a unique molecular marker for this disease. The development of efficient methods for its detection in free circulating DNA of patients may lead to the improvement of diagnostic and prognostic tools. With this aim, we evaluated whether BRAFV600E represents a detectable marker in the plasma/serum from melanoma patients in a pilot study. Circulating cell‐free DNA was extracted from the serum or plasma of 15 healthy donors and 41 melanoma patients at different clinical stages and obtained either presurgery or after surgery during follow‐up. Quantitative analysis showed higher levels of circulating free DNA in patients compared to controls, with the highest levels detected in samples obtained presurgery and at stage IV. Four different PCR methods were compared for their capacity to amplify a few copies of BRAFV600E in wild‐type DNA. BRAFV600E was detectable in circulating DNA of 12 patients and in none of the controls; only 1 PCR method reproducibly amplified BRAFV600E. Positive samples were obtained from 8/13 patients at stage IV and from 4/24 patients at stage III, but not in 4 patients at stage I–II; half of the positives were obtained presurgery and half at follow‐up. Correspondence between circulating DNA and related tumors were examined for 20 patients, and a correlation was found for stage IV patients. In conclusion, this method can be utilized for monitoring the disease in stage IV melanoma patients but it appears unsatisfactory for the early detection of melanoma. © 2007 Wiley‐Liss, Inc.

show abstract

Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcription-polymerase chain reaction

Cited by 14 publications

References 26 publications

Detection of candidate melanoma blood biomarkers by RNA-Sequencing

Detection of candidate melanoma blood biomarkers by RNA-Sequencing

Tumor cell and circulating markers in melanoma: Diagnosis, prognosis, and management

Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients

Contact Info

Product

Resources

About